NASDAQ · GALT
Healthcare · Biotechnology
$3.68
Down-$0.05 (-1.34%)
Updated Sep 17, 2026, 8:45 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GALT closed at $3.68 after 20 trading sessions, up 0.27% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $3.71 | $3.80 | $3.6106 | $3.68 | 276.07K |
| Sep 15, 2026 | $3.82 | $3.825 | $3.5801 | $3.73 | 327.23K |
| Sep 14, 2026 | $3.95 | $4.09 | $3.82 | $3.84 | 338.53K |
| Sep 11, 2026 | $3.92 | $4.01 | $3.84 | $3.91 | 243.77K |
| Sep 10, 2026 | $4.00 | $4.0499 | $3.84 | $3.90 | 253.05K |
| Sep 9, 2026 | $4.13 | $4.34 | $4.035 | $4.05 | 515.69K |
| Sep 8, 2026 | $4.60 | $4.65 | $4.10 | $4.14 | 393.42K |
| Sep 4, 2026 | $4.33 | $4.72 | $4.33 | $4.61 | 473.55K |
| Sep 3, 2026 | $4.50 | $4.60 | $4.224 | $4.35 | 244.15K |
| Sep 2, 2026 | $4.19 | $4.53 | $4.19 | $4.48 | 460.7K |
| Sep 1, 2026 | $3.91 | $4.385 | $3.91 | $4.17 | 479.58K |
| Aug 31, 2026 | $4.02 | $4.05 | $3.91 | $3.95 | 229.71K |
| Aug 28, 2026 | $4.14 | $4.20 | $3.95 | $4.02 | 271.19K |
| Aug 27, 2026 | $4.15 | $4.45 | $4.04 | $4.14 | 345.23K |
| Aug 26, 2026 | $3.95 | $4.205 | $3.92 | $4.15 | 291.11K |
| Aug 25, 2026 | $4.07 | $4.19 | $3.845 | $3.99 | 194.72K |
| Aug 24, 2026 | $3.68 | $3.97 | $3.58 | $3.88 | 227.96K |
| Aug 21, 2026 | $3.62 | $3.74 | $3.5871 | $3.68 | 174.93K |
| Aug 20, 2026 | $3.67 | $3.7493 | $3.44 | $3.57 | 313.11K |
| Aug 19, 2026 | $3.54 | $3.77 | $3.54 | $3.67 | 353.79K |
The latest Smart Investors Daily articles mentioning GALT.
GALT research
Company profile and research snapshot.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 17, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 2, 2025 | HC Wainwright & Co. | Neutral | — |
| Dec 27, 2024 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · Feb 26, 2026
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader
SeekingAlpha · Dec 4, 2025
Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis.
seekingalpha.com · Dec 4, 2025
Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis. GALT reported a narrower Q3 loss due to lower R&D and operating expenses post-trial, with a cash runway through mid-2026 after securing a $10M credit line. Belapectin demonstrated reductions in liver stiffness, fibrogenesis, and new varices, especially in high-risk patients, while maintaining a favorable safety profile.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GALT.
